LGBTQ Nation

U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress

The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
STAT

South Africa is urged by advocates to issue a compulsory license for Gilead’s HIV prevention drug

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Zacks Investment Research on MSN

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Medscape

Important Long-COVID Lessons From AIDS Researchers

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).